Catalyst Crew Technologies Corp. (OTC: CCTC) has announced the development of PulmoAI, an artificial intelligence-enabled module designed to support the detection and predictive analysis of pulmonary diseases. The platform is part of the company's broader digital health ecosystem and aims to assist healthcare providers in analyzing respiratory health data and identifying potential clinical risks through AI-driven analytics.
PulmoAI is being developed to integrate multiple data inputs, including computed tomography (CT) scans, chest X-rays, pulmonary function tests, and inflammatory biomarkers. The system is intended to generate structured outputs that support clinical review and care coordination. According to the company, the platform's proposed capabilities include automated interpretation of thoracic imaging, detection of pulmonary abnormalities, and predictive modeling of disease progression.
The module is expected to function as a specialized component within Catalyst Crew's digital health ecosystem, which includes a healthcare services coordination platform. Management believes that modular AI systems like PulmoAI could enable scalable deployment across telehealth services, remote diagnostics, and technology-enabled healthcare delivery environments. The company intends to integrate PulmoAI across its existing and planned healthcare infrastructure initiatives.
Catalyst Crew Technologies is prioritizing market development in Latin America, where AI-enabled healthcare technologies may help expand access to respiratory diagnostics and support earlier identification of pulmonary conditions. Dr. Kevin Rodan Levy, CEO of Catalyst Crew Technologies, stated: "Artificial intelligence has the potential to enhance how healthcare providers detect and monitor pulmonary conditions, particularly in environments where access to specialized diagnostics may be limited. PulmoAI reflects our commitment to building scalable, technology-driven solutions to support healthcare delivery."
The company plans to continue developing and refining PulmoAI while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. More information is available on the company's website at https://catalystcrewai.com or through its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Catalyst Crew Technologies Corp. is an AI-driven healthcare technology company focused on developing scalable digital health solutions for emerging markets, with an initial emphasis on Latin America. The company is executing a strategic transition into AI-enabled healthcare and pursuing opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms.
